Kinarus Therapeutics Holding AG in Liquidation reverse takeover (RTO) transaction with Curatis AG

Share on:

On 29 January 2024, Kinarus Therapeutics Holding AG in liquidation (Kinarus) announced that it has entered into a transaction agreement (Transaction Agreement) with Curatis AG (Curatis) regarding a contemplated combination transaction. Curatis is a privately owned specialty pharmaceutical company focusing predominantly on orphan/ultra-orphan diseases and specialty care diseases. Under the terms of the Transaction Agreement, shareholders of Curatis shall exchange each outstanding Curatis share into one newly issued Kinarus share, whereby the consideration consists of approx.

14x the number of outstanding Kinarus shares. It is planned that Kinarus will be renamed to Curatis Holding AG. The transaction is expected to close in Q2 2024. Closing is subject to certain closing conditions, inter alia, confirmation of withdrawal of bankruptcy for Kinarus by the courts of Basel-Stadt, approval of all proposed resolutions by the extraordinary general meeting of Kinarus and approval of the listing of the new shares by SIX Swiss Exchange.

Discover more articles

We provide up-to-date information on legal and regulatory developments regarding the capital markets, publish concise articles on developments in the Swiss and international financial markets, and announce recent deals and forthcoming events.

  • BX DIGITAL: THE FIRST DLT TRADING FACILITY IN SWITZERLAND

    BX Digital AG received the first license from FINMA to operate a DLT trading facility on 12 March 2025. It is also the first financial market infrastructure for the trading and settlement of DLT securities based on a public permissionless blockchain.


  • Proposed Amendment of Swiss Capital Adequacy Ordinance regarding AT1 Instruments – a First Assessment by Practitioners

    On 6 June 2025, the Swiss Federal Council published proposed amendments to the Swiss Capital Adequacy Ordinance, including „more precise information on the term and suspension of interest payments for AT1 capital instruments.“ The authors question the necessity of these changes and warn against using opaque terms and „hard triggers“ without any exemptions.


  • Zürcher Kantonalbank‘s issuance of EUR 500 million Bonds  

    On 8 July 2025, Zürcher Kantonalbank successfully completed its issuance of EUR 500 million 2.762%. Fixed Rate Bonds due 2030 (the Bonds). The senior unsecured bonds have been issued under Zürcher Kantonalbank‘s Swiss base prospectus consisting of the applicable summary and securities note for the issue of bonds and STNs of Zürcher Kantonalbank dated 20…


  • Merger of Aebi Schmidt Group and The Shyft Group with Listing on NASDAQ

    On 1 July 2025, the Swiss specialty vehicle manufacturer Aebi Schmidt announced the successful completion of its merger with The Shyft Group, thereby creating a world-class specialty vehicles leader with sales of approx. USD 2 billion per year and 70 locations worldwide. The shares of the combined Aebi Schmidt Group (NASDAQ: AEBI) started trading on…


  • Ultima Capital‘s Contribution of Nammos Mykonos

    Ultima Capital SA (Ultima), a Swiss luxury real estate owner and operator listed on BX Swiss, conducted its second contribution in kind of real estate assets by its largest shareholder Yoda PLC (Yoda). The contributed assets are pertaining to the Nammos Village and restaurant real estate in Mykonos, Greece. The assets were valued at EUR 133.7…


  • Raiffeisen‘s Inaugural Issuance of Green Bonds

    On 27 June 2025, Raiffeisen Schweiz Genossenschaft successfully completed its issuance of CHF 250 million 0.785% fixed rate green bonds due 2030 under its issuance program for money market instruments, bonds and green bonds. This issuance marks the first issuance of a green bond by Raiffeisen Schweiz Genossenschaft.  Raiffeisen Schweiz Genossenschaft acted as Sole Lead Manager…